Rheumo, Golfer(pathetic), Caravaggisti, Prof School of Medicine Griffith University, A/Prof Univ. of Qld, Director Rheumatology Research Unit Sunshine Coast,
OP002 (2026)
ANIFROLUMAB TREATMENT IN PATIENTS WITH SJÖGREN’S DISEASE: EFFICACY AND SAFETY ASSESSMENT IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIA PROOF-OF-MECHANISM TRIAL (ANISE-II) anifrolumab works in SjD - high interferon signature works the best? #EULAR2026
POS0109 (2025)
COMPARATIVE PERSISTENCE AND EFFECTIVENESS OF IXEKIZUMAB VERSUS OTHER b/tsDMARD CLASSES IN REAL-WORLD PsA TREATMENT: 12-MONTH RESULTS FROM THE PRO-SPIRIT STUDY - a practical comparison #ixekizumab#TNF#IL23i
OP0091 (2025)
MARKERS OF IL-17 SIGNALLING IN THE BLOOD OF PATIENTS WITH PSORIATIC ARTHRITIS WITH INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS
interesting - 17F raised in TNF non-responders PsA - #IL17F#PsA#TNF-IR
Varenna, M., Zucchi, F., Di Taranto, R. et al. Osteoclast in CRPS: an alleged guilty fully acquitted. Osteoporos Int 36, 737–740 (2025). https://t.co/LaqqkYOcjv its not the Osteoclast! but perhaps dependent on acute vs chronic changes
From DNA to PGA
David Pisetsky, MD, PhD
May 07, 2025
📷
Investigating the mechanisms of antinuclear antibody (ANA) expression in SLE since 1978..MTP session on the Type 1 & 2 model for SLE - relevant for CAR-T &
D2T vs C2M in SLE as well as RA PsA AxSpA #RheumNow # SLE #D2T
A new toxicity syndrome in patients with autoimmune disease treated with CAR T-cell therapy - The Lancet Rheumatology https://t.co/zi0ZLDGqv7 We need comparative studies! #CAR-T #LICATS
Human Papillomavirus Vaccination and Actinic Keratosis Burden https://t.co/x5sCFXxqao affects many of our patients MTX, TNFs, JAKs + QLD sun ! #IMID#HPVvax#RheumNow
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine https://t.co/YK7CDxc1xj not seen in IMID CAR-T cell therapy yet but instructive nevertheless